Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.

Clinical trials have demonstrated that rituximab improves overall survival in non-Hodgkin lymphoma (NHL), except in mantle cell lymphoma (MCL). We used Surveillance Epidemiology and End Results (SEER)-Medicare data to compare survival in older MCL patients who began chemotherapy with or without ritu...

Popoln opis

Bibliografske podrobnosti
Main Authors: Griffiths, R, Mikhael, J, Gleeson, M, Danese, M, Dreyling, M
Format: Journal article
Jezik:English
Izdano: 2011